DoriVac DNA nanostructure vaccine platform shows strong immune responses in early studies

A vaccine delivery platform called DoriVac, which uses folded DNA nanostructures rather than lipid nanoparticles or viral vectors, has produced strong antibody and T-cell responses in both mouse models and human cell cultures. The results, published in Nature Nanotechnology, are early-stage data, but they are notable because they suggest that DNA origami, a technique for folding single strands of DNA into precise three-dimensional shapes, can function as a practical vaccine delivery architecture rather than just a laboratory curiosity.

The platform addresses a specific set of problems that have limited existing vaccine technologies. mRNA vaccines, which proved effective during the COVID-19 pandemic, require ultra-cold storage, ranging from minus 20 to minus 70 degrees Celsius depending on formulation, because mRNA molecules degrade quickly at higher temperatures. They also require lipid nanoparticles to protect the mRNA and help it enter cells, and those particles have been associated with inflammatory responses in some recipients. DoriVac uses a structurally more stable delivery vehicle and has shown adequate stability at refrigerator temperatures in preliminary testing.

What DNA origami actually is and how DoriVac uses it

DNA origami was first described by Paul Rothemund at Caltech in a 2006 Nature paper. The technique uses a long single strand of DNA as a scaffold and dozens of shorter complementary strands as staples to fold the scaffold into a specific two-dimensional or three-dimensional shape. The resulting structures are precise to the nanometre scale and can be programmed to display molecules on their surfaces in defined positions and orientations.

DoriVac attaches antigen proteins and adjuvant molecules directly to the surface of a DNA origami nanostructure in a controlled spatial arrangement. The spacing between antigens can be tuned to match the spacing between B-cell receptors on immune cells, which determines how effectively the immune system recognises and responds to the antigen. Standard subunit vaccines present antigens in solution, where their orientation and spacing relative to immune cell receptors is random. DoriVac's structured presentation is designed to produce a stronger and more consistent immune activation per dose.

What the immune response data showed

In mouse studies, DoriVac-vaccinated animals produced antibody titres approximately four to six times higher than controls receiving the same antigen in a standard adjuvanted formulation. T-cell responses, measured by interferon-gamma production from splenocytes after antigen re-exposure, were also significantly elevated in the DoriVac group. T-cell responses matter for vaccines against intracellular pathogens and for cancer immunotherapy, where antibody-mediated responses alone are often insufficient.

In human peripheral blood mononuclear cell cultures, DoriVac constructs activated dendritic cells and promoted cytokine profiles consistent with a Th1-skewed immune response, which is the type associated with effective clearance of viral infections and tumour cells. The human cell data cannot predict clinical outcomes, but it confirms that the nanostructure does not simply fail to engage human immune machinery, which is a real concern when translating mouse immunology findings.

The cold chain problem and what DoriVac offers instead

Cold chain failures remain a major constraint on vaccine access in low and middle income countries. The WHO estimates that between 25 and 35 percent of vaccines are damaged by temperature excursions during transport and storage in low-resource settings. An mRNA vaccine requiring minus 70 degree storage is simply not deployable in most rural health clinics in sub-Saharan Africa or South Asia without substantial infrastructure investment.

DoriVac's DNA origami scaffold is chemically more stable than mRNA. The research team reported that DoriVac constructs retained structural integrity and immunostimulatory activity after storage at 4 degrees Celsius for four weeks, which is standard refrigerator temperature. They also retained partial activity after one week at room temperature. Those numbers need to be confirmed in longer stability studies before they can be cited in a regulatory submission, but they suggest that the cold chain requirement could be substantially less demanding than for mRNA vaccines.

Cancer vaccine applications the researchers are pursuing

The research team at Dana-Farber Cancer Institute and Harvard's Wyss Institute for Biologically Inspired Engineering, which jointly developed DoriVac, is specifically interested in neoantigen cancer vaccines. Neoantigens are mutant proteins expressed by tumour cells but not normal cells. Personalised cancer vaccines that train the immune system to recognise a patient's specific tumour neoantigens have shown early promise in clinical trials. Moderna and Merck reported in a 2023 New England Journal of Medicine paper that their mRNA-based personalised cancer vaccine reduced recurrence in melanoma patients by 44 percent compared to pembrolizumab alone.

DoriVac's ability to display multiple different antigen peptides at defined positions on a single nanostructure could allow a personalised cancer vaccine to present a panel of neoantigens simultaneously in a spatially organised way that promotes cross-reactive T-cell responses. The team has begun testing DoriVac constructs loaded with melanoma neoantigens in a mouse tumour model and plans to submit those results for publication in late 2026. A first-in-human Phase 1 safety trial is targeted for 2027, subject to IND approval from the FDA.